Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

June 23, 2026

Study Completion Date

June 24, 2026

Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
OTHER

Aromatherapy inhaler

Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. They will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (total of six days). Given the subjective nature of scents, participants in the intervention group will be given a choice between two therapeutic aroma blends - N1 and N2 - before commencing the study. This approach aims to minimize the risk of negative associations with a particular scent and enhance participant adherence to the intervention.

OTHER

Aromatherapy inhaler (placebo)

Participants in the control group will receive the placebo intervention in addition to standard care. They will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has littleto- no scent and no known therapeutic or anxiolytic effects when inhaled.

Trial Locations (1)

169608

Singapore General Hospital, Singapore

All Listed Sponsors
collaborator

National Cancer Centre, Singapore

OTHER

lead

Singapore General Hospital

OTHER